Latest filing published 18 Jan 2023 for Mersana Therapeutics, Inc..
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Arvin Yang: trading record in brief
Arvin Yang discloses dealings in Mersana Therapeutics, Inc. to SEC (Form 4). Over a trading history stretching from 30 November 2021 to 17 January 2023, the count stands at 6 filings.
Sales make up the whole of the open-market record (3 sales, €80k). Besides market trades, the filings include 3 option exercises. In 2023 alone, the filings show no purchases and 1 sale.
On 18 January 2023 came the latest disclosure, an open-market sale for €12k in Mersana Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Arvin Yang
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 7,084 shares0Common StockSEC:0001104659-23-004747:0
- 18,500 shares0Common StockSEC:0001104659-22-124083:0
- 18,500 sharesCommon StockSEC:0001104659-21-145951:0
3 of 3 declarations
